Recent advances in transthyretin amyloidosis therapy

Translational Neurodegeneration

Yukio Ando¹  Mitsuharu Ueda² 

[1] Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, 860-0811 Kumamoto, Japan;Department of Diagnostic Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, 860-0811 Kumamoto, Japan

关键词: Gene therapy;    Immunotherapy;    Senile systemic amyloidosis;    Familial amyloidotic polyneuropathy;    Amyloidosis;    Transthyretin;   

Others  :  1132770
DOI  :  10.1186/2047-9158-3-19

 received in 2014-06-09, accepted in 2014-09-10,  发布年份 2014

【 摘 要 】

Mutant (MT) forms of transthyretin (TTR) cause the most common type of autosomal-dominant hereditary systemic amyloidosis—familial amyloidotic polyneuropathy (FAP). Until 20 years ago, FAP was thought to be an endemic disease, but FAP is known to occur worldwide. To date, more than 130 mutations in the TTR gene have been reported. Genotype-phenotype correlations are seen in FAP, and some variation in clinical presentation is often observed in individual kindreds with the same mutation and even among family members. Of the pathogenic TTR mutations, Val30Met was the first to be identified and is the most frequent known mutation found throughout the world. Studies of patients with FAP amyloidogenic TTR (ATTR) Val30Met documented sensorimotor polyneuropathy, autonomic dysfunction, heart and kidney failure, gastrointestinal tract (GI) disorders, and other symptoms leading to death, usually within 10 years of the onset of disease. Diagnosis is sometimes delayed, especially in patients without a clear family history and typical clinical manifestations, since diagnosis requires various studies and techniques such as histopathology, genetic testing, and mass spectrometry. For treatment of FAP, liver transplantation (LT) reportedly halts the progression of clinical manifestations. Exchange of an FAP patient’s diseased liver with a healthy liver causes MT TTR in the body to be replaced by wild-type (WT) TTR. Although clinical evaluations indicated that progression of other clinical symptoms such as peripheral neuropathy, GI symptoms, and renal involvement usually halted after LT in FAP ATTR Val30Met patients, recent studies suggested that LT failed to prevent progression of cardiac amyloidosis in FAP ATTR Val30Met patients after LT, with this failure reportedly being due to continued formation of amyloid that derived mainly from WT TTR secreted from the transplanted non-mutant liver graft. In recent years, many therapeutic strategies have been proposed, and several ongoing therapeutic trials involve, for example, stabilizers of TTR tetramers (tafamidis and diflunisal) and gene therapies to suppress TTR expression (antisense methods and use of small interfering RNAs). These novel therapies may prove to prevent progression of FAP.

【 授权许可】

   
2014 Ueda and Ando; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ando Y, Nakamura M, Araki S: Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005, 62:1057-1062.
• [2]Zeldenrust S, Benson MD: Familial and senile amyloidosis caused by transthyretin. In Protein Misfolding Diseases: Current and Emerging Principles and Therapies. Edited by Alvarado M, Kelly JW, Dobson CM. Hoboken, NJ: John Wiley & Sons; 2010:795-815.
• [3]Planté-Bordeneuve V, Said G: Familial amyloid polyneuropathy. Lancet Neurol 2011, 10:1086-1097.
• [4]Ando Y, Ueda M: Diagnosis and therapeutic approaches to transthyretin amyloidosis. Curr Med Chem 2012, 19:2312-2323.
• [5]Ando Y: Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol 2005, 38:142-154.
• [6]Merlini G, Westermark P: The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004, 255:159-178.
• [7]Benson MD: Amyloidosis in arthritis and allied conditions. In A Textbook of Rheumatology. Edited by Koopman WJ. Philadelphia: Lippincott Williams & Wilkins; 2001:1866-1895.
• [8]Sipe JD, Cohen AS: Review: history of the amyloid fibril. J Struct Biol 2000, 130:88-98.
• [9]Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P, Nomenclature Committee of the International Society of Amyloidosis: Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012, 19:167-170.
• [10]Westermark P: Aspect of the history and nomenclature of amyloid and amyloidosis. In Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Current Clinical Pathology. Edited by Picken MM, Dogan A, Herrera GA. New York: Springer Science + Business Media; 2012:3-8.
• [11]Benson MD: The hereditary amyloidoses. In Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Current Clinical Pathology. Edited by Picken MM, Dogan A, Herrera GA. New York: Springer Science + Business Media; 2012:53-67.
• [12]Westermark P, Picken MM, Dogan A, Herrera GA: Localized amyloidoses and amyloidoses associated with aging outside the central nervous system. In Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Current Clinical Pathology. New York: Springer Science + Business Media; 2012:81-103.
• [13]Richardson SJ: TTR synthesis during development and evolution: what the marsupials revealed. In Recent Advances in Transthyretin Evolution, Structure and Biological Functions. Edited by Richardson SJ, Cody V. Heidelberg: Springer; 2009:173-189.
• [14]Dickson PW, Schreiber G: High levels of messenger RNA for transthyretin (prealbumin) in human choroid plexus. Neurosci Lett 1986, 66:311-315.
• [15]Ong DE, Davis JT, O’Day WT, Bok D: Synthesis and secretion of retinol-binding protein and transthyretin by cultured retinal pigment epithelium. Biochemistry 1994, 33:1835-1842.
• [16]Westermark GT, Westermark P: Transthyretin and amyloid in the islets of Langerhans in type-2 diabetes. Exp Diabetes Res 2008, 2008:429274.
• [17]Zanotti G, Berni R: Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitam Horm 2004, 69:271-295.
• [18]Myron Johnson A, Merlini G, Sheldon J, Ichihara K: Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med 2007, 45:419-426.
• [19]Westermark P, Bergström J, Solomon A, Murphy C, Sletten K: Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003, 10:48-54.
• [20]Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, Shinriki S, Kawahara S, Jono H, Obayashi K, Ogawa H, Ando Y: Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 2011, 24:1533-1544.
• [21]Lai Z, Colón W, Kelly JW: The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996, 35:6470-6482.
• [22]Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y: Polyneurotic amyloidosis in a Japanese family. Arch Neurol 1968, 18:593-602.
• [23]Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE: Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10:160-184.
• [24]Mutations in Hereditary Amyloidosis [http://amyloidosismutations.com/attr.html webcite]
• [25]Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G, Study Group for Hereditary Neuropathy in Japan: Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 2002, 59:1771-1776.
• [26]Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J, Kawanami T, Kato T, Yamamoto M, Sobue G: Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012, 83:152-158.
• [27]Hellman U, Suhr O: Regional differences and similarities of FAP in Sweden. Amyloid 2012, 19:53-54.
• [28]Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson BO, Westermark P: Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005, 206:224-232.
• [29]Ihse E, Suhr OB, Hellman U, Westermark P: Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) 2011, 89:171-180.
• [30]Oshima T, Kawahara S, Ueda M, Kawakami Y, Tanaka R, Okazaki T, Misumi Y, Obayashi K, Yamashita T, Ohya Y, Ihse E, Shinriki S, Tasaki M, Jono H, Asonuma K, Inomata Y, Westermark P, Ando Y: Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation. J Neurol Neurosurg Psychiatry 2014, 85:740-746.
• [31]Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB: Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2012, 93:1017-1023.
• [32]Westermark P, Sletten K, Johansson B, Cornwell GG 3rd: Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990, 87:2843-2845.
• [33]Falk RH: Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 2011, 124:1079-1085.
• [34]Dubrey SW, Hawkins PN, Falk RH: Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011, 97:75-84.
• [35]Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A: Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010, 7:398-408.
• [36]Sueyoshi T, Ueda M, Sei A, Misumi Y, Oshima T, Yamashita T, Obayashi K, Shinriki S, Jono H, Shono M, Ando Y, Mizuta H: Spinal multifocal amyloidosis derived from wild-type transthyretin. Amyloid 2011, 18:165-168.
• [37]Lin JR, Wang H, Collins AB, Stone JR: Tongue necrosis and systemic vascular amyloidosis. Hum Pathol 2011, 42:734-737.
• [38]Tirzaman O, Wahner-Roedler DL, Malek RS, Sebo TJ, Li CY, Kyle RA: Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 2000, 75:1264-1268.
• [39]Roden AC, Aubry MC, Zhang K, Brady JO, Levin D, Dogan A, Yi ES: Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study. Hum Pathol 2010, 41:1040-1045.
• [40]Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, Ando Y, Mizuta H: Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol 2011, 42:1259-1264.
• [41]Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, Hoshii Y, Kato H, Ikeda S: High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 2011, 42:1785-1791.
• [42]Ando Y, Ueda M: Proteomics for transthyretin (TTR) related amyloidosis. Curr Proteomics 2011, 8:237-246.
• [43]Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G: Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011, 18:53-62.
• [44]Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G: Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007, 69:693-698.
• [45]Grateau G, Stankovic: Diagnosis and classification. In myloidosis: Diagnosis and Treatment. Edited by Gertz M, Rajkumar SV. New York: Springer Science + Business Media; 2010:33-48.
• [46]Westermark P: Subcutaneous adipose tissue biopsy for amyloid protein studies. Methods Mol Biol 2012, 849:363-371.
• [47]Kyle RA, Spencer RJ, Dahlin DC: Value of rectal biopsy in the diagnosis of primary systemic amyloidosis. Am J Med Sci 1966, 251:501-506.
• [48]Röcken C, Sletten K: Amyloid in surgical pathology. Virchows Arch 2003, 443:3-16.
• [49]Lechapt-Zalcman E, Authier FJ, Creange A, Voisin MC, Gherardi RK: Labial salivary gland biopsy for diagnosis of amyloid polyneuropathy. Muscle Nerve 1999, 22:105-107.
• [50]Gertz MA: The classification and typing of amyloid deposits. Am J Clin Pathol 2004, 121:787-789.
• [51]Murphy CL, Eulitz M, Hrncic R, Sletten K, Westermark P, Williams T, Macy SD, Wooliver C, Wall J, Weiss DT, Solomon A: Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin Pathol 2001, 116:135-142.
• [52]Linke RP, Oos R, Wiegel NM, Nathrath WB: Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 2006, 108:197-208.
• [53]Kaplan B, Shtrasburg S, Pras M: Micropurification techniques in the analysis of amyloid proteins. J Clin Pathol 2003, 56:86-90.
• [54]Kaplan B, Martin BM, Livneh A, Pras M, Gallo GR: Biochemical subtyping of amyloid in formalin-fixed tissue samples confirms and supplements immunohistologic data. Am J Clin Pathol 2004, 121:794-800.
• [55]Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A: Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009, 114:4957-4959.
• [56]Dogan A, Picken MM, Dogan A, Herrera GA: Classification of amyloidosis by mass spectrometry-based proteomics. In Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Current Clinical Pathology. New York: Springer Science + Business Media; 2012:261-272.
• [57]Klein CJ, Vrana JA, Theis JD, Dyck PJ, Dyck PJ, Spinner RJ, Mauermann ML, Bergen HR 3rd, Zeldenrust SR, Dogan A: Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011, 68:195-199.
• [58]Ando Y, Ohlsson PI, Suhr O, Nyhlin N, Yamashita T, Holmgren G, Danielsson A, Sandgren O, Uchino M, Ando M: A new simple and rapid screening method for variant transthyretin-related amyloidosis. Biochem Biophys Res Commun 1996, 228:480-483.
• [59]Yamashita T, Ando Y, Bernt Suhr O, Nakamura M, Sakashita N, Ohlsson PI, Terazaki H, Obayashi K, Uchino M, Ando M: A new diagnostic procedure to detect unknown transthyretin (TTR) mutations in familial amyloidotic polyneuropathy (FAP). J Neurol Sci 2000, 173:154-159.
• [60]Bergquist J, Andersen O, Westman A: Rapid method to characterize mutations in transthyretin in cerebrospinal fluid from familial amyloidotic polyneuropathy patients by use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2000, 46:1293-1300.
• [61]Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, Ota K, Shinriki S, Jono H, Ikeda S, Suhr OB, Ando Y: SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem 2009, 55:1223-1227.
• [62]Ericzon G, Lundgren E, Suhr O: Liver transplantation for transthyretin amyloidosis. In Recent Advances in Transthyretin Evolution, Structure and Biological Functions. Edited by Richardson SJ, Cody V. Heidelberg: Springer; 2009:239-260.
• [63]Stangou AJ, Hawkins PN: Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004, 17:615-620.
• [64]Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, Yamashita T, Ueda M, Okabe H, Sasaki Y, Tanihara H, Uchino M, Inomata Y: A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation 2004, 77:345-349.
• [65]Said G, Planté-Bordeneuve V: Familial amyloid polyneuropathy: a clinico-pathologic study. J Neurol Sci 2009, 284:149-154.
• [66]Familial Amyloidotic Polyneuropathy World Transplant Registry [http://www.fapwtr.org/ webcite]
• [67]Suhr OB, Friman S, Ericzon BG: Early liver transplantation improves familial amyloidotic polyneuropathy patients’ survival. Amyloid 2005, 12:233-238.
• [68]Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, Nakamura M, Jono H, Shono M, Asonuma K, Inomata Y, Uchino M: Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012, 78:637-643.
• [69]Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Söderdahl G, Wikström L, Ando Y, Suhr OB, Ericzon BG: Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007, 7:2597-2604.
• [70]Wilczek H, Larsson M, Ericzon B: Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 2011, 18:188-190.
• [71]Benson MD: Liver transplantation and transthyretin amyloidosis. Muscle Nerve 2013, 47:157-162.
• [72]Ohya Y, Okamoto S, Tasaki M, Ueda M, Jono H, Obayashi K, Takeda K, Okajima H, Asonuma K, Hara R, Tanihara H, Ando Y, Inomata Y: Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation. Surg Today 2011, 41:1211-1218.
• [73]Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, Planté V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, Said G: The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000, 123:1495-1504.
• [74]de Carvalho M, Conceição I, Bentes C, Luís ML: Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid 2002, 9:126-133.
• [75]Suhr OB, Anan I, Ahlström KR, Rydh A: Gastric emptying before and after liver transplantation for familial amyloidotic polyneuropathy, Portuguese type (Val30Met). Amyloid 2003, 10:121-126.
• [76]Nowak G, Suhr OB, Wikström L, Wilczek H, Ericzon BG: The long-term impact of liver transplantation on kidney function in familial amyloidotic polyneuropathy patients. Transpl Int 2005, 18:111-115.
• [77]Hörnsten R, Wiklund U, Olofsson BO, Jensen SM, Suhr OB: Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation 2004, 78:112-116.
• [78]Liepnieks JJ, Benson MD: Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007, 14:277-282.
• [79]Morris AM, Watzky MA, Finke RG: Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim Biophys Acta 2009, 1794:375-397.
• [80]Hurshman AR, White JT, Powers ET, Kelly JW: Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004, 43:7365-7381.
• [81]Monteiro E, Perdigoto R, Furtado AL: Liver transplantation for familial amyloid polyneuropathy. Hepatogastroenterology 1998, 45:1375-1380.
• [82]Stangou AJ, Heaton ND, Hawkins PN: Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005, 352:2356.
• [83]Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, Nanjo H, Asonuma K, Inomata Y, Watanabe S, Uchino M, Tanaka K, Ando Y: Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant 2006, 6:2512-2515.
• [84]Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, Hoshii Y: Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl 2007, 13:215-218.
• [85]Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW: The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012, 421:185-203.
• [86]Quintas A, Saraiva MJ, Brito RM: The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J Biol Chem 1999, 274:32943-32949.
• [87]Baures PW, Oza VB, Peterson SA, Kelly JW: Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 1999, 7:1339-1347.
• [88]Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR: Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012, 79:785-792.
• [89]Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceiçao I, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Grogan DR: Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013, 260:2802-2814.
• [90]Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ, Diflunisal Trial Consortium: Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013, 310:2658-2667.
• [91]Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
• [92]Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
• [93]Kurosawa T, Igarashi S, Nishizawa M, Onodera O: Selective silencing of a mutant transthyretin allele by small interfering RNAs. Biochem Biophys Res Commun 2005, 337:1012-1018.
• [94]Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, Geissler M, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, et al.: Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013, 369:819-829.
• [95]Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP: Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012, 19:43-44.
• [96]Benson MD, Kluve-Beckerman B, Zeldenrust SR: Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006, 33:609-618.
• [97]Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop KW, Monia BP: Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid 2010, 17:43-49.
• [98]Haraoka K, Ando Y, Ando E, Sun X, Nakamura M, Terazaki H, Misumi S, Tanoue Y, Tajiri T, Shoji S, Ishizaki T, Okabe H, Tanihara H: Presence of variant transthyretin in aqueous humor of a patient with familial amyloidotic polyneuropathy after liver transplantation. Amyloid 2002, 9:247-251.
• [99]Kawaji T, Ando Y, Hara R, Tanihara H: Novel therapy for transthyretin-related ocular amyloidosis: a pilot study of retinal laser photocoagulation. Ophthalmology 2010, 117:552-555.
• [100]Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG, Garini P, Diegoli M, Trizio D, Ballinari D: Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995, 92:2959-2963.
• [101]Sebastiao MP, Merlini G, Saraiva MJ, Damas AM: The molecular interaction of 4′-iodo-4′-deoxydoxorubicin with Leu-55Pro transthyretin ’amyloid-like’ oligomer leading to disaggregation. Biochem J 2000, 351:273-279.
• [102]Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM: Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002, 160:1089-1095.
• [103]Cardoso I, Merlini G, Saraiva MJ: 4′-Iodo-4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species. Screening for TTR fibril disrupters. FASEB J 2003, 17:803-809.
• [104]Cardoso I, Saraiva MJ: Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 2006, 20:234-239.
• [105]Macedo B, Batista AR, Ferreira N, Almeida MR, Saraiva MJ: Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy. Biochim Biophys Acta 2008, 1782:517-522.
• [106]Uekama K, Hirayama F, Irie T: Cyclodextrin drug carrier systems. Chem Rev 1998, 98:2045-2076.
• [107]Davis ME, Brewster ME: Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004, 3:1023-1035.
• [108]Jono H, Anno T, Motoyama K, Misumi Y, Tasaki M, Oshima T, Mori Y, Mizuguchi M, Ueda M, Shono M, Obayashi K, Arima H, Ando Y: Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Biochem J 2011, 437:35-42.
• [109]Nakamura M, Ando Y, Nagahara S, Sano A, Ochiya T, Maeda S, Kawaji T, Ogawa M, Hirata A, Terazaki H, Haraoka K, Tanihara H, Ueda M, Uchino M, Yamamura K: Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther 2004, 11:838-846.
• [110]Gustavsson A, Engström U, Westermark P: Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations. Am J Pathol 1994, 144:1301-1311.
• [111]Redondo C, Damas AM, Olofsson A, Lundgren E, Saraiva MJ: Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. J Mol Biol 2000, 304:461-470.
• [112]Terazaki H, Ando Y, Fernandes R, Yamamura K, Maeda S, Saraiva MJ: Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 2006, 86:23-31.
• [113]Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB: Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010, 468:93-97.